Table 1 Patients’ clinical and biological characteristics
Initial characteristics | |
Tumor biology group, n (%) | |
HER2+ HR+ | 58 (23.2) |
HER2+ HR- | 61 (24.4) |
HER2- HR+ | 64 (25.6) |
Triple negative | 67 (26.8) |
ER status, n (%) | |
Negative | 128 (51.2) |
Positive | 122 (48.8) |
PR status, n (%) | |
Negative | 186 (74.7) |
Positive | 63 (25.3) |
Missing | 1 |
HER2 status, n (%) | |
Negative | 131 (52.4) |
Positive | 119 (47.6) |
Histological subtype, n (%) | |
Ductal carcinoma | 203 (82.9) |
Other subtypesa | 42 (17.1) |
Missing | 5 |
Histological grade (SBR), n (%) | |
1 or 2 | 103 (45.8) |
3 | 122 (54.2) |
Missing | 25 |
Inflammatory BC, n (%) | |
No | 216 (90.8) |
Yes | 22 (9.2) |
Missing | 12 |
Metastatic status at BC diagnosis, n (%) | |
M0 | 174 (71.3) |
M1 | 70 (28.7) |
Mx | 6 |
Patients’ characteristics at the time of the serum sample | |
Median age in years (range) | 58.4 (26.4–87.2) |
Age group, n (%) | |
< 50 | 77 (30.8) |
50 to 70 | 132 (52.8) |
> 70 | 41 (16.4) |
Median number of lines of CT (range) | 1 (0–9) |
Number of lines of CT, n (%) | |
0 line | 61 (24.4) |
1 or 2 line(s) | 113 (45.2) |
> 2 lines | 76 (30.4) |
Previous anti-HER2 treatment, n (%) | |
No | 149 (59.6) |
Yes | 101 (40.4) |
Brain metastases, n (%) | 88 (35.2) |
Liver metastases, n (%) | 152 (60.8) |
Bone metastases, n (%) | 142 (56.8) |
Lung metastases, n (%) | 125 (50.0) |
Lymph node metastases, n (%) | 134 (53.6) |
Subcutaneous metastases, n (%) | 43 (17.2) |
Pleural metastases, n (%) | 55 (22.0) |
Metastases of other sites, n (%) | 109 (43.6) |
ECOG status, n (%) | |
0 | 70 (30.2) |
1 | 106 (45.7) |
2 | 34 (14.7) |
3 | 22 (9.5) |
Missing | 18 |
Anemia, n (%) | |
No | 38 (25.9) |
Yes | 109 (74.1) |
Missing | 103 |
Leucopenia, n (%) | |
No | 118 (82.5) |
Yes | 25 (17.5) |
Missing | 107 |
Neutropenia, n (%) | |
No | 129 (89.0) |
Yes | 16 (11.0) |
Missing | 105 |
Lymphopenia, n (%) | |
No | 82 (59.4) |
Yes | 56 (40.6) |
Missing | 112 |
Thrombopenia, n (%) | |
No | 128 (88.3) |
Yes | 17 (11.7) |
Missing | 105 |
Elevated LDH, n (%) | |
No | 51 (56.7) |
Yes | 39 (43.3) |
Missing | 160 |
Elevated serum CEA, n (%) | |
No | 154 (66.4) |
Yes | 78 (33.6) |
Missing | 18 |
Elevated serum CA 15-3, n (%) | |
No | 92 (39.7) |
Yes | 140 (60.3) |
Missing | 18 |
Elevated serum HER2 ECD (cut-off 15 ng/mL) | |
No | 107 (42.8) |
Yes | 143 (57.2) |
Missing | 0 |
Elevated serum HER2 ECD (cut-off 30 ng/mL) | |
No | 187 (74.8) |
Yes | 63 (25.2) |
Missing | 0 |
Elevated serum NSE (cut-off 12.5 μg/L) | |
No | 76 (30.5) |
Yes | 173 (69.5) |
Missing | 1 |
Elevated serum MMP9 (cut-off 50 ng/mL) | |
No | 6 (2.4) |
Yes | 244 (97.6) |
Missing | 0 |
Elevated serum S100ß (cut-off 0.12 μg/L) | |
No | 224 (92.2) |
Yes | 19 (7.8) |
Missing | 7 |
Elevated serum S100ß (cut-off 0.072 μg/L) | |
No | 183 (75.3) |
Yes | 60 (24.7) |
Missing | 7 |
Low protein level, n (%) | |
No | 32 (74.4) |
Yes | 11 (25.6) |
Missing | 119 |
Low albumin level, n (%) | |
No | 135 (85.4) |
Yes | 23 (14.6) |
Missing | 92 |
Follow-up | |
Status as last follow-up, n (%) | |
Alive | 77 (30.8) |
Dead | 173 (69.2) |
Cause of death, n (%) | (174 deceased) |
Oncological disease | 153 (87.9) |
Non-oncological | 4 (2.3) |
Toxic | 4 (2.3) |
Unknown | 13 (7.5) |